The FDA has approved ImClone's Erbitux for head and neck cancer, the first new therapy for those indications in almost half a century. "This is the first drug approved for head and neck cancer that has shown a survival benefit in this population," the FDA said. The approval came for head and neck cancer that couldn't be removed by surgery. Merck, which markets the therapy in Europe, said last week that a European drug committee issued a favorable opinion of Erbitux for head and neck cancer. Erbitux was originally approved for colorectal cancer.
- read this report from TheStreet.com for more information